21 November 2024 in Gut Microbes
The consumption of high-fat diets (HFD) and an imbalance in gut microbiome are linked to obesity. However, the intricate connection between them and the underlying mechanisms involved in lipid digestion and absorption remain largely unclear. This study shows that after 12 weeks of HFD feeding, C57BL/6J mice exhibit two distinct metabolic phenotypes with significant differences in gut microbiota composition. The LOW and LOW FMT group mice with increased Bacteroides are protected from obesity, insulin resistance, and lipid accumulation. Supplementation with B. vulgatus or cholic acid (CA) alleviates HFD-induced obesity and metabolic dysfunction. This is due to the accumulation of lipid droplets and the retention of chyle particles in jejunal epithelial cells, which reduces chyle intake in the jejunal mesentery after HFD. Decreased 5-HT synthesis in the jejunal enterochromaffin cells of these mice, along with reduced chyle intake in the jejunal mesentery after HFD in Tph1△IEC, suggests that intestinal 5-HT is required for host lipid absorption. TRPV1, a calcium-permeable ion channel, mediates the basolateral 5-HT-induced increase of Isc and ion channel open probability. This study uncovers a novel signaling axis of microbiota-metabolite-5-HT and intracellular calcium-dependent lipid absorption, which may serve as the potential therapeutic targets for treating HFD-induced obesity.
15 June 2026 in Cell Death & Disease
The consensus molecular subtype 4 (CMS4) of colorectal cancer (CRC) represents an aggressive, mesenchymal phenotype associated with the poorest clinical prognosis. Although angiogenesis is fundamental to CRC progression, current anti-VEGF therapies are frequently compromised by primary or acquired resistance, creating an urgent need to identify alternative vascular drivers. NOTCH3 is significantly enriched in CMS4 CRC, yet its direct role in modulating the tumor vasculature remains elusive. Here, integrating multi-center transcriptomic datasets with clinical validation, we identified NOTCH3 as a critical engine of CRC angiogenesis. In Stage IV clinical samples, NOTCH3 expression correlated significantly with microvessel density (MVD). Functionally, overexpression of the NOTCH3 intracellular domain (NICD3) dramatically enhanced endothelial tube formation and migration in vitro, while driving robust tumor vascularization in xenograft models. Through transcriptomic profiling, we identified the secreted factor transforming growth factor-beta-induced protein (TGFBI) as the essential downstream effector. Mechanistically, we demonstrate that NICD3 physically interacts with and upregulates SMAD3, thereby facilitating the direct transcriptional activation of TGFBI. Crucially, to translate these mechanistic insights, we utilized molecular docking and drug screening to identify the flavonoid Hesperidin (HES) as a potent binder of TGFBI. HES treatment effectively abolished NICD3-driven angiogenesis and suppressed tumor progression in vivo. Collectively, our findings characterize a novel NICD3/SMAD3/TGFBI signaling axis as a key vulnerability in CRC and propose HES as a promising precision therapeutic strategy for CRC patients with features of CMS4.